Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Adagio Medical Holdings ( (ADGM) ) has shared an announcement.
On December 11, 2025, Adagio Medical Holdings, Inc. expanded its Board of Directors from six to seven members, appointing Sean Salmon as a Class II director. Salmon, with extensive experience at Medtronic, will also serve on the Audit and Compensation Committees. This strategic appointment is expected to enhance the company’s governance and operational oversight.
The most recent analyst rating on (ADGM) stock is a Sell with a $0.83 price target. To see the full list of analyst forecasts on Adagio Medical Holdings stock, see the ADGM Stock Forecast page.
Spark’s Take on ADGM Stock
According to Spark, TipRanks’ AI Analyst, ADGM is a Underperform.
Adagio Medical Holdings faces significant financial and operational challenges, reflected in its low financial performance and valuation scores. While recent corporate events show potential for future growth, the current financial instability and bearish technical indicators weigh heavily on the overall stock score.
To see Spark’s full report on ADGM stock, click here.
More about Adagio Medical Holdings
Average Trading Volume: 366,755
Technical Sentiment Signal: Sell
Current Market Cap: $19.15M
Learn more about ADGM stock on TipRanks’ Stock Analysis page.